Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q4 2025 Earnings Presentation
9 slides from Avita Medical's earnings presentation, Feb 12, 2026
Slide 1: Fourth Quarter and Full Year 2025 Financial and Business Update
Fourth Quarter and Full Year 2025 Financial and Business Update February 12, 2026
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: Delivering on Q4 2025 priorities, positioned for growth in 2026
Delivering on Q4 2025 priorities, positioned for growth in 2026 Drive disciplined execution o Business stabilized; execution phase underway o Year-end growth sustained with greater than 80% gross margin Refine our commercial focus o Commercial model oriented to organic core-account growth o Multi-pr
Slide 4: AVITA continued sales growth with above 80% gross margin
AVITA continued sales growth with above 80% gross margin Net Revenue Gross margin USD million 82.0% 82.0% 82.4% 84.5% 85.8% 82.1%* +32% +11% +28% +46% +35% +46% 18 2020** 2021** 2022 2023 2024 2025 2020** 2021** 2022 2023 2024 2025 USD mn 18 26 35 50 64 72 *Decrease in gross margin caused by product
Slide 5: Financial results reflecting full year revenue growth and cost discipline
Financial results reflecting full year revenue growth and cost discipline FY Key figures Q4 Q4 FY FY 2026 USD million 2024 2025 2024 2025 (Estimate) Revenue $18.4 $17.6 $64.3 $71.6 $80 to $85 Gross profit margin* 87.6% 81.2% 85.8% 82.1% Operating $26.1 $24.7** $111.8 $101.4 expenses Net loss ($11.6)
Slide 6: Continued focus on cash use
Continued focus on cash use Cash, and marketable securities at quarter end USD million Cash use $10.1m Cash use $6.2m Cash use $5.1m $13.8 Equity raise* $25.8 $23.3 $18.2 $15.7 Q1 Q2 Q3 Q4 *Raised $13.8 million, net after expenses, through a private placement completed in August AVITA Medical| Febru
Slide 7: New debt facility with Perceptive Advisors LLC on better terms
New debt facility with Perceptive Advisors LLC on better terms Key loan terms Rationale Amount: $60 million ($50 million at close); optional $10 million Maturity: 5 years from close Refinance existing debt on better terms Interest rate: SOFR + 7.5% Amortization: None, interest only Additional workin
Slide 8: Summary
Summary Delivered a more Exited 2025 with Advanced post-market Entered 2026 with an stable revenue reimbursement clarity clinical programs for improved commercial performance in Q4, and early signs of Cohealyx and model and capital with improved utilization normalizing PermeaDerm, with structure to
Slide 9: Transforming lives.